MARKET

OVID

OVID

Ovid Therapeutics Inc
NASDAQ
2.340
-0.020
-0.85%
Pre Market: 2.350 +0.01 +0.43% 07:02 10/09 EDT
OPEN
2.320
PREV CLOSE
2.360
HIGH
2.360
LOW
2.290
VOLUME
1.32K
TURNOVER
0
52 WEEK HIGH
3.105
52 WEEK LOW
1.180
MARKET CAP
457.00M
P/E (TTM)
-9.2308
1D
5D
1M
3M
1Y
5Y
1D
Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating
Benzinga · 5h ago
Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 5h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)
TipRanks · 1d ago
Ovid Therapeutics management to meet with B. Riley
TipRanks · 3d ago
Ovid Therapeutics Initiated at Buy by Guggenheim
Dow Jones · 3d ago
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7
Benzinga · 3d ago
Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential
TipRanks · 3d ago
Ovid Therapeutics Price Target Announced at $7.00/Share by Guggenheim
Dow Jones · 3d ago
More
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Webull offers Ovid Therapeutics Inc stock information, including NASDAQ: OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.